libretto-001: targeting ret fusions in advanced-stage nsclc
Published 4 years ago • 306 plays • Length 3:58Download video MP4
Download video MP3
Similar videos
-
5:06
libretto-001: ret-fusion positive metastatic nsclc
-
1:48
selpercatinib induced durable efficacy in ret fusion-positive nsclc
-
3:05
dr. drilon discusses the results of the phase i/ii libretto-001 trial
-
3:49
ret fusion treatment: selpercatinib - targeted therapies in lung cancer 2023
-
3:58
highlights on selpercatinib in ret fusion-positive nsclc: the libretto-431 study
-
1:09:43
mia: fabian theis, reconstructing trajectories and branching lineages in single cell genomics
-
1:04:59
single cell & spatial multiplex profiling of immune cell markers in ffpe tumors - rnascope hiplex v2
-
3:30
lung cancer targeted gene panel with rearrangement [a test in focus]
-
6:59
other targeted approaches in nsclc: ntrk or ret fusions
-
4:58
treatment of nsclc with ret fusions
-
1:06
dr. oxnard discusses ret fusions in nsclc
-
2:12
the impact of selpercatinib in patients with ret fusion-positive nsclc
-
7:02
fda approval of selpercatinib for ret fusion positive nsclc and thyroid cancers
-
7:34
intracranial activity of selpercatinib in ret fusion positive nsclc
-
2:52
updated overall efficacy and safety of selpercatinib in patients with ret fusion nsclc
-
9:54
efficacy and safety of selpercatinib in ret fusion-positive cancers other than lung or thyroid c...
-
2:07
ret inhibitors in development
-
6:42
selpercatinib benefit, with or without pembro, in first-line advanced ret fusion-positive nsclc
-
5:39
wclc 2019: libretto-001: a phase 1/2 trial of loxo-292 in patients with ret fusion-positive lung...
-
2:48
ret fusion-positive mnsclc: selpercatinib and pralsetinib
-
1:02:07
selpercatinib in ret-altered thyroid cancers with dr. lori wirth
-
2:21
pralsetinib in chinese patients with advanced ret fusion nsclc